GSK126EZH2 inhibitor CAS# 1346574-57-9 |
- 3-Deazaneplanocin,DZNep
Catalog No.:BCC1129
CAS No.:102052-95-9
- GSK343
Catalog No.:BCC1607
CAS No.:1346704-33-3
- EPZ005687
Catalog No.:BCC2219
CAS No.:1396772-26-1
- EPZ-6438
Catalog No.:BCC3634
CAS No.:1403254-99-8
- EI1
Catalog No.:BCC4044
CAS No.:1418308-27-6
- UNC1999
Catalog No.:BCC4552
CAS No.:1431612-23-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1346574-57-9 | SDF | Download SDF |
| PubChem ID | 68210102 | Appearance | Powder |
| Formula | C31H38N6O2 | M.Wt | 526.67 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | EZH2 inhibitor; GSK2816126A | ||
| Solubility | DMSO : 12.5 mg/mL (23.73 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide | ||
| SMILES | CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C | ||
| Standard InChIKey | FKSFKBQGSFSOSM-QFIPXVFZSA-N | ||
| Standard InChI | InChI=1S/C31H38N6O2/c1-6-22(5)37-18-20(3)29-25(30(38)34-17-26-19(2)13-21(4)35-31(26)39)14-24(15-27(29)37)23-7-8-28(33-16-23)36-11-9-32-10-12-36/h7-8,13-16,18,22,32H,6,9-12,17H2,1-5H3,(H,34,38)(H,35,39)/t22-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | GSK126 is a potent, highly selective inhibitor of EZH2 methyltransferase activity with IC50 of 9.9 nM.In Vitro:GSK126 potently inhibits both wild-type and mutant EZH2 methyltransferase activity with similar potencies (Ki=0.5-3 nM) independent of substrate used, and is competitive with S-adenosyl-methionine (SAM) and non-competitive with peptide substrates. GSK126 is highly selective against other methyltransferases and multiple other protein classes (EZH1, IC50=680 nM)[1]. Treatment of three SCLC cell lines with GSK126, induces growth inhibition. SCLC cell lines (Lu130, H209, and DMS53) are treated with 0.5, 2, and 8 μM GSK126, and growth curve is analyzed by WST-8 assay. Inhibition of cellular growth by GSK126 treatment is observed at 8 μM in all the three cell lines, while Lu130 and H209 are more sensitive to GSK126, even at lower doses[2].In Vivo:GSK126 is administered intraperitoneally at a dose volume of 0.2 mL per 20 g body weight in female beige SCID mice. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice[1]. References: | |||||
| Kinase experiment [1]: | |
| Inhibitory activities | Biochemical assays used the five-member PRC2 complex (human Flag-EZH2, EED, SUZ12, AEBP2, RbAp48) containing either wild-type or mutant EZH2, [3H]-SAM and histone H3 peptides (21-44) with K27me0, K27me1 or K27me2 were used as substrates, reactions were incubated for 30 min. Global histone modification levels were determined by enzyme-linked immunosorbent assay (ELISA) or western blot methods using antibodies specific for total histoneH3, H3K27me1, H3K27me2 orH3K27me3. |
| Cell experiment [2]: | |
| Cell lines | Lu130, H209, and DMS53 small cell lung cancer (SCLC) cell lines. |
| Preparation method | Dissolved in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
| Reacting condition | 0.5, 2, and 8 μM; 72, 144, 192 h. |
| Applications | GSK126 inhibited cell growth in all the three cell lines at 8 μM. |
| Animal experiment [1]: | |
| Animal models | Mice using subcutaneous xenografts of KARPAS-422 and Pfeiffer cells. |
| Dosage form | 15, 50, 150 mg/kg, 10 days of once daily; 300 mg/kg twice per week; administered intraperitoneally. |
| Application | GSK126 decreases H3K27me3 and increases gene expression in a dose-dependent way. GSK126 completely inhibited tumour growth at 50 mg/kg and increases survival of mice bearing the more aggressive KARPAS-422 tumours. GSK126 was well tolerated at the doses and schedules examined as measured by little to no decrease in body weight. |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: [1]. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 2012, 492(7427): 108-112. [2]. Sato T, Kaneda A, Tsuji S, et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep, 2013, 3: 1911. | |
GSK126 Dilution Calculator
GSK126 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8987 mL | 9.4936 mL | 18.9872 mL | 37.9744 mL | 47.4681 mL |
| 5 mM | 0.3797 mL | 1.8987 mL | 3.7974 mL | 7.5949 mL | 9.4936 mL |
| 10 mM | 0.1899 mL | 0.9494 mL | 1.8987 mL | 3.7974 mL | 4.7468 mL |
| 50 mM | 0.038 mL | 0.1899 mL | 0.3797 mL | 0.7595 mL | 0.9494 mL |
| 100 mM | 0.019 mL | 0.0949 mL | 0.1899 mL | 0.3797 mL | 0.4747 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GSK126 is an inhibitor of EZH2 with Ki Value of 93 pM [1].
Over-expression of EZH2 has been reported to be correlated with cancer progression and poor prognosis, high grade and high stage in several tumor types. GSK126 is a potent inhibitor of EZH2 and its functional residence time on activated form of EZH2/PRC2 is mush longer than unactivated forms [1]. When tested with lymphoma cell lines, results showed that harboring EZH2 mutations such as Y641N, Y641F or A677G were more sensitivity [2]. In DMS53, Lu30, H209 SCLC cells, cellular growth was inhibited with 0.5, 2, and 8μM GSK126 treatment [3]. And GSK126 could also significantly restore ARNTL expression in ovarian cancer cells thus inhibit cell growth and enhance chemosensitivity of cisplatin [4].
Intermittent dosing of GSK126 treated subcutaneous KARPAS-422 xenografts model could effectively inhibit its growth with or without a 1 week drug holiday. In mouse model with EZH2 mutant DLBCL xenografts, treatment with GSK126 could markedly inhibit its growth [2].
References:
1. Sato, T., et al., PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep, 2013. 3(1911).
2. McCabe, M.T., et al., EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 2012. 492(7427): p. 108-12.
3. Van Aller, G.S., et al., Long residence time inhibition of EZH2 in activated polycomb repressive complex 2. ACS Chem Biol, 2014. 9(3): p. 622-9.
4. Yeh, C.M., et al., Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer. Int J Oncol, 2014. 45(5): p. 2101-7.
- GSK503
Catalog No.:BCC6386
CAS No.:1346572-63-1
- ML 240
Catalog No.:BCC5604
CAS No.:1346527-98-7
- Zinc Pyrithione
Catalog No.:BCC5008
CAS No.:13463-41-7
- Eriocitrin
Catalog No.:BCN1208
CAS No.:13463-28-0
- Stavudine sodium
Catalog No.:BCC4263
CAS No.:134624-73-0
- ML 218 hydrochloride
Catalog No.:BCC6207
CAS No.:1346233-68-8
- SA 57
Catalog No.:BCC6280
CAS No.:1346169-63-8
- Planchol E
Catalog No.:BCN6882
CAS No.:1346137-02-7
- LY2795050
Catalog No.:BCC1719
CAS No.:1346133-08-1
- ML 154
Catalog No.:BCC8022
CAS No.:1345964-89-7
- 5,7-Di-O-methylquercetin
Catalog No.:BCN3386
CAS No.:13459-07-9
- CYM 50308
Catalog No.:BCC6260
CAS No.:1345858-76-5
- GSK621
Catalog No.:BCC6517
CAS No.:1346607-05-3
- GSK343
Catalog No.:BCC1607
CAS No.:1346704-33-3
- Lamivudine
Catalog No.:BCC3801
CAS No.:134678-17-4
- Linderane
Catalog No.:BCN5023
CAS No.:13476-25-0
- A 412997 dihydrochloride
Catalog No.:BCC6224
CAS No.:1347744-96-0
- 6''-O-Acetylglycitin
Catalog No.:BCN3866
CAS No.:134859-96-4
- 8-M-PDOT
Catalog No.:BCC6901
CAS No.:134865-70-6
- 4-P-PDOT
Catalog No.:BCC6900
CAS No.:134865-74-0
- SAR245409
Catalog No.:BCC2534
CAS No.:934493-76-2
- Taccalonolide AJ
Catalog No.:BCN2971
CAS No.:1349904-82-0
- 2,2'-Dithiobisbenzanilide
Catalog No.:BCC8497
CAS No.:135-57-9
- Pseudotropine
Catalog No.:BCN1932
CAS No.:135-97-7
Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.[Pubmed:27926488]
Oncotarget. 2017 Jan 10;8(2):3396-3411.
EZH2 is a critical epigenetic regulator that is deregulated in various types of cancers including multiple myeloma (MM). In the present study, we hypothesized that targeting EZH2 might induce apoptosis in myeloma cells including stem cell-like cells (CSCs). We investigated the effect of EZH2 inhibition on MM cells using a potent inhibitor (GSK126). The results showed that GSK126 effectively abrogated the methylated histone 3 (H3K27me3) level in MM.1S and LP1 cells, and inhibited the number of live cells and colony formation in soft agar of six MM cell lines. GSK126 induced massive apoptosis in MM.1S, LP1 and RPMI8226 cells. Progressive release of mitochondrial cytochrome c and AIF into the cytosol was detected in GSK126-treated MM cells. GSK126 treatment elicited caspase-3-dependent MCL-1 cleavage with accumulation of proapoptotic truncated MCL-1. These results suggested that GSK126 triggers the intrinsic mitochondrial apoptosis pathway. Enhanced apoptosis was observed in the combination of GSK126 with bortezomib. Using ALDH and side population (SP) assays to characterize CSCs, we found that GSK126 eliminated the stem-like myeloma cells by blocking the Wnt/beta-catenin pathway. The in vivo anti-tumor effect of GSK126 was confirmed by using RPMI8226 cells in a xenograft mouse model. In conclusion, our findings suggest that EZH2 inactivation by GSK126 is effective in killing MM cells and CSCs as a single agent or in combination with bortezomib. Clinical trial of GSK126 in patients with MM may be warranted.
The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A.[Pubmed:26898301]
Cancer Chemother Pharmacol. 2016 Apr;77(4):757-65.
PURPOSE: To explore the effects and mechanisms of GSK126, a novel inhibitor of histone methyltransferase enhancer of zeste homologue 2, on cancer cell migration. METHODS: Gastric cancer cell line MGC803 and human lung adenocarcinoma cell line A549 were treated with GSK126 at three doses. Transwell and wound healing assays were conducted to detect cell migration. Human umbilical vein endothelial cells tube formation assay and chick embryo chorioallantoic membrane assay were performed to assess the effects of GSK126 on angiogenesis in vitro and in vivo, respectively. The mRNA level of VEGF-A was detected by quantitative PCR, and the protein levels of VEGF-A were detected both by western blot analysis and immunohistochemistry. Epi-fluorescent intensity was obtained by in vivo imaging. RESULTS: GSK126 inhibited cell migration in both MGC803 and A549 in a dose-dependent manner, as revealed by transwell and wound healing assays. The effects of GSK 126 were similar to those of gefitinib at the same doses. Moreover, GSK126 at doses of 20 and 50 microM inhibited angiogenesis both in vitro and in vivo. GSK126 reduced both the mRNA and protein expression of VEGF-A in a dose-dependent manner. Finally, in vivo imaging assay revealed that GSK126 at 200 mg/kg significantly inhibited cancer cell migration. CONCLUSIONS: GSK126 inhibits cell migration and angiogenesis in solid tumor cell lines through down-regulation of VEGF-A expression. Thus, it may be considered as a novel anticancer drug candidate for solid tumor.
[Effect of a novel EZH2 inhibitor GSK126 on prostate cancer cells].[Pubmed:27868408]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016 May 25;45(4):356-363.
Objective: To investigate the effect of a novel EZH2 inhibitor GSK126 on cell growth, apoptosis and migration of prostate cancer cells. Methods: Prostate cancer PC-3 and DU145 cells were treated with GSK126 at different doses. Cell growth was detected by sulforhodamine assay. Cell apoptosis was assayed by Annexin V-/PI kit. Transwell chamber and wound healing assays were conducted to detect cell migration. The mRNA level was detected by quantitative PCR, and protein expression was detected by Western blot analysis. Results: GSK126 showed significant effect on cell growth and apoptosis when the dose was higher than 50 mumol/L. Wound healing assay revealed that scratch space in PC-3 cells was significantly increased in a dose-dependent manner in GSK126-treated groups[(247.2+/-24.4),(347.2+/-19.2) and (410.5+/-18.1) mum in low, medium and high dose (5.0, 20.0, 50.0 mumol/L), respectively] as compared with the control group[(171.3+/-17.8) mum](all P<0.05). Transwell assay showed that migrated PC-3 cells in control group was 322.0+/-17.9,while those in GSK126-treated groups were 198.3+/-15.4 (low),82.7+/-6.2 (medium) and 30.2+/-4.1 (high), and the differences between the control group and GSK126-treated groups were significant(all P<0.05). In addition, GSK126 up-regulated E-cadherin mRNA expression and down-regulated N-cadherin and Vimentin mRNA expression, whereas had no significant effect on Snail, Fibronectin and VEGF-A mRNA expression. The protein expression of E-cadherin was elevated but VEGF-A protein did not change in GSK126-treated groups. Similar results were exhibited in DU145 cell. Conclusion: GSK126 can significantly inhibit cell migration and invasion in prostate cancer PC-3 and DU145 cells, which may be resulted from its effect on epithelial-mesenchymal transition. GSK126 may be used as a potential anti-prostate cancer dug in clinic.
